Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, P. J.
The Proceedings of the American Thoracic Society 1:264-268 (2004)
© 2004 The American Thoracic Society

Corticosteroid Resistance in Airway Disease

Peter J. Barnes

National Heart and Lung Institute, Imperial College, London, United Kingdom

Correspondence and requests for reprints should be addressed to Professor P. J. Barnes, D.M., D.Sc., F.R.C.P., National Heart and Lung Institute, Imperial College, Dovehouse Street, London SW3 6LY, UK. E-mail: p.j.barnes{at}imperial.ac.uk

Resistance to the antiinflammatory effects of corticosteroids is very uncommon in asthma but common in chronic obstructive pulmonary disease. Recent understanding of the molecular mechanisms involved in the antiinflammatory actions of corticosteroids has revealed that there are several possible mechanisms for corticosteroid resistance. Certain cytokines activate p38 mitogen-activated protein kinase, which may interfere with the nuclear localization of glucocorticoid receptors (GRs). In other patients, nuclear localization of GR is normal but there is a reduction in acetylation of a lysine residue in histone-4, thus leading to impaired activation of certain antiinflammatory genes. In chronic obstructive pulmonary disease and severe asthma, oxidative stress may reduce the activity and expression of certain histone deacetylases and therefore interfere with the antiinflammatory action of corticosteroids. These mechanisms suggest that there may be several therapeutic approaches to treating corticosteroid resistance in the future, including antioxidants, p38 mitogen-activated protein kinase inhibitors, and theophylline, which activates histone deacetylases.

Key Words: steroid resistance • asthma • chronic obstructive pulmonary disease • histone deacetylase




This article has been cited by other articles:


Home page
 Therapeutic Advances in Respiratory DiseaseHome page
G. Braganza, R. Chaudhuri, and N. C. Thomson
Review: Treating patients with respiratory disease who smoke
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 95 - 107.
[Abstract] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
O. Tliba, G. Damera, A. Banerjee, S. Gu, H. Baidouri, S. Keslacy, and Y. Amrani
Cytokines Induce an Early Steroid Resistance in Airway Smooth Muscle Cells: Novel Role of Interferon Regulatory Factor-1
Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 463 - 472.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L.-b. Li, D. Y. M. Leung, M. J. Strand, and E. Goleva
ATF2 impairs glucocorticoid receptor mediated transactivation in human CD8+ T cells
Blood, September 1, 2007; 110(5): 1570 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Chanez and P. Godard
Is difficult asthma still clinically meaningful?
Eur. Respir. J., November 1, 2006; 28(5): 897 - 899.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Thoracic Society.